US Patent

US9550759 — Nitrocatechol derivatives as COMT inhibitors

Method of Use · Assigned to Bial Portela and Cia SA · Expires 2026-07-26 · 0y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent describes new compounds with potentially valuable pharmaceutical properties for treating central and peripheral nervous system disorders.

USPTO Abstract

New compounds of formula I are described. The compounds have potentially valuable pharmaceutical properties in the treatment of some central and peripheral nervous system disorders.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3870`	—
`U-3870`	—

Patent Metadata

Patent number: US9550759
Jurisdiction: US
Classification: Method of Use
Expires: 2026-07-26
Drug substance claim: No
Drug product claim: No
Assignee: Bial Portela and Cia SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.